Cancer Biomarkers, a leading journal in the field of oncology, has announced its transition to Gold Open Access starting January 1, 2024. With this shift, all articles published from Volume 39, Issue 1 onwards will be immediately and permanently available online for free, allowing unrestricted access to researchers, healthcare professionals, and the public. This move is set to enhance the journal's impact and accessibility, benefiting the global cancer research community.
Published by IOS Press, which recently became part of Sage, Cancer Biomarkers is recognized as one of the most influential journals dedicated exclusively to cancer research. The transition to Open Access aligns with the growing demand for freely accessible scientific content and will enable authors to comply more easily with funder and institutional mandates.
The journal maintains its rigorous peer-review process and commitment to rapid manuscript processing times. Accepted papers will be published under a Creative Commons CC BY-NC 4.0 license, allowing authors to retain copyright of their work while permitting readers to download, share, and reuse the content with appropriate attribution. Authors also have the option to select a CC BY 4.0 license, which is required by certain funding bodies.
To support this transition, an introductory Open Access Fee, also known as an Article Processing Charge (APC), has been set at US$1500 / €1500 for the CC BY-NC 4.0 license. The CC BY 4.0 license is available for US$2150 / €2150. These fees are valid until September 1, 2024, after which they will increase to US$2800 / €2800 for the CC BY-NC 4.0 license. Certain publication types, such as editorials and letters, will not incur any fees, and waivers may be available for authors from low-income countries as defined by Research4Life.
With the integration of IOS Press into Sage, authors affiliated with institutions that have Open Access agreements with Sage may have some or all of their APC covered by their institution, depending on the terms of the agreement.
The transition to Gold Open Access is a significant milestone for Cancer Biomarkers, as it underscores the journal’s commitment to advancing cancer research by making cutting-edge discoveries more accessible to a broader audience. This change is expected to accelerate the dissemination of research findings, ultimately benefiting patients and their families worldwide.
Click here to read the original press release.
